Illumina Inc
F:ILU

Watchlist Manager
Illumina Inc Logo
Illumina Inc
F:ILU
Watchlist
Price: 132.28 EUR 1.38% Market Closed
Market Cap: €21.1B

Net Margin

16.4%
Current
Improving
by 56.4%
vs 3-y average of -40%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.4%
=
Net Income
$703m
/
Revenue
$4.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16.4%
=
Net Income
€703m
/
Revenue
$4.3B

Peer Comparison

Country Company Market Cap Net
Margin
US
Illumina Inc
NASDAQ:ILMN
22.9B USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
165.5B USD
Loading...
CH
Lonza Group AG
SIX:LONN
37.6B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Higher than 79% of companies in the United States of America
Percentile
79th
Based on 15 072 companies
79th percentile
16.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Illumina Inc
Glance View

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILU Intrinsic Value
116.44 EUR
Overvaluation 12%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16.4%
=
Net Income
$703m
/
Revenue
$4.3B
What is Illumina Inc's current Net Margin?

The current Net Margin for Illumina Inc is 16.4%, which is above its 3-year median of -40%.

How has Net Margin changed over time?

Over the last 3 years, Illumina Inc’s Net Margin has increased from -88.4% to 16.4%. During this period, it reached a low of -100.9% on Apr 2, 2023 and a high of 29.4% on Jun 29, 2025.

Back to Top